Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures

Core Insights - Royal Philips has launched the VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe, enhancing real-time 3D imaging capabilities for cardiac procedures without the need for general anesthesia [1][6]. Product Features - The VeriSight Pro catheter is designed for procedures like transcatheter valve repair and left atrial appendage closure, providing high-resolution 2D and 3D visualization directly within heart chambers [2][4]. - It features a miniaturized ultrasound probe, approximately 3 millimeters in diameter, allowing for detailed imaging from within the heart [4][13]. - Unique technologies such as xPlane and iRotate enable simultaneous visualization of two imaging planes and digital adjustments without repositioning the catheter [8]. Clinical Impact - The introduction of VeriSight Pro addresses the growing challenge of structural heart disease in Europe, facilitating procedures that traditionally required general anesthesia and extended recovery times [3][5]. - The catheter reduces the burden on patients and healthcare facilities by shortening hospital stays and lowering costs associated with traditional imaging methods [3][5]. Integration and Ecosystem - VeriSight Pro is part of Philips' integrated portfolio for structural heart care, working seamlessly with EPIQ ultrasound systems and the Azurion image-guided therapy platform [7]. - This integration supports a comprehensive solution for various cardiac procedures, enhancing workflow and clinical outcomes [7]. Upcoming Events - Philips will showcase the VeriSight Pro at EuroPCR 2025 in Paris, highlighting its application in real-world structural heart procedures [9][14].